Effects of amphetamine and 6-hydroxydopamine lesions on reserpine-induced oral dyskinesia

European Journal of Pharmacology

Volumn 305, Issue 1-3, 1996, Pages 13-21

  Neisewander, Janet L ^a   Castañeda, Edward ^a   Davis, Debra A ^a   Elson, Heather J ^a   Sussman, Amy N ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

Author keywords

6 hydroxydopamine; amphetamine; caudate putamen; dopamine; nigrostriatal; oral dyskinesia; rat; reserpine; tardive dyskinesia; tongue protrusion

Indexed keywords

AMPHETAMINE; DOPAMINE; LEVODOPA; OXIDOPAMINE; RESERPINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BRAIN INJURY; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; LOCOMOTION; MALE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OROFACIAL DYSKINESIA; PRIORITY JOURNAL; RAT; STEREOTYPY; SUBCUTANEOUS DRUG ADMINISTRATION; TARDIVE DYSKINESIA;

EID: 0343586513     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/0014-2999(96)00155-0     Document Type: Article

References (64)

1. Arbuthnott, G.W., I.S. Fairbrother and S.P. Butcher, 1991, Dopamine release and metabolism in the rat striatum: an analysis by 'in vivo' brain microdialysis, Pharmacol. Ther. 48, 281.
2. Arnold, E.B., P.B. Molinoff and C.O. Rutledge, 1977, The release of endogenous norepinephrine and dopamine from cerebral cortex by amphetamine, J. Pharmacol. Exp. Ther. 202, 544.
3. Arnt, J., 1985, Behavioral stimulation is induced by separate D-1 and D-2 receptor sites in reserpine-pretreated but not in normal rats, Eur. J. Pharmacol. 113, 79.
4. Baldessarini, R.J., J.O. Cole, J.M. Davis, G. Simpson, D. Tarsy, G. Gardos and S.H. Preskorn, 1980, Tardive dyskinesia: summary of a task force report of the American Psychiatric Association, Am. J. Psychiatry 137, 1163.
5. Bean, A.J., M.J. During, A.Y. Deutch and R.H. Roth, 1989, Effects of dopamine depletion on striatal neurotensin: biochemical and immunohistochemical studies, J. Neurosci. 9, 4430.
6. Burt, D.R., I. Creese and S.H. Snyder, 1977, Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain, Science 196, 326.
7. Butcher, S.P., I.S. Fairbrother, J.S. Kelly and G.W. Arbuthnott, 1988, Amphetamine-induced dopamine release in the rat striatum: an in vivo microdialysis study, J. Neurochem. 50, 346.
8. Cadoni, C., A. Pinna, G. Russi, S. Consolo, and G. Di Chiara, 1995, Role of vesicular dopamine in the in vivo stimulation of striatal dopamine transmission by amphetamine: evidence from microdialysis and fos immunohistochemistry, Neuroscience 65, 1027.
9. Callaway, C.W., R. Kuczenski and D.S. Segal, 1989, Reserpine enhances amphetamine stereotypies without increasing amphetamine-induced changes in striatal dialysate dopamine, Brain Res. 505, 83.
10. Castañeda, E., I.Q. Whishaw and T.E. Robinson, 1990, Changes in striatal dopamine neurotransmission assessed with microdialysis following recovery from a bilateral 6-OHDA lesion: variation as a function of lesion size, J. Neurosci. 10, 1847.
11. Costall, B. and R.J. Naylor, 1977, Mesolimbic and extrapyramidal sites for the mediation of stereotyped behavior patterns and hyperactivity by amphetamine and apomorphine in the rat, in: Cocaine and Other Stimulants, ed. E.H. Ellinwood and MM Kilbey (Plenum Press, New York) p. 47.
12. Creese, I. and S.D. Iversen, 1974, The role of forebrain dopamine systems in amphetamine induced stereotyped behavior in the rat, Psychopharmacologia 39, 345.
13. Dluzen, D.E. and F.T. Kratko, Jr., 1992, L-DOPA infusion mode differentially affects corpus striatal dopamine efflux in the presence of reserpine, J. Neural Transm. 89, 197.
14. Ellison, G., P. Johansson, E. Levin, R. See and L. Gunne, 1988, Chronic neuroleptics alter the effects of the D1 agonist SK and F 38393 and the D2 agonist LY171555 on oral movements in rats, Psychopharmacology 96, 253.
15. Fibiger, H.C. and Lloyd, K.G., 1984, Neurobiological substrates of tardive dyskinesia: the GABA hypothesis, Trends Neurosci. 7, 462.
16. Fisher, J.F. and A.K. Cho, 1979, Chemical release of dopamine from striatal homogenates: evidence for an exchange-diffusion model, J. Pharmacol. Exp. Ther. 208, 203.
17. Florin, S.M., R. Kuczenski and D.S. Segal, 1995, Effects of reserpine on extracellular caudate dopamine and hippocampus norepinephrine responses to amphetamine and cocaine: mechanistic and behavioral consideration, J. Pharmacol. Exp. Ther. 274, 231.
18. Florin, S.M., R. Kuczenski and D.S. Segal, 1994, Regional extracellular norepinephrine responses to amphetamine and cocaine and effects of clonidine pretreatment, Brain Res. 654, 53.
19. Gardos, G. and J.O. Cole, 1983, The prognosis of tardive dyskinesia, J. Clin. Psychiatry 44, 177.
20. Gerlach, J. and D.E. Casey, 1988, Tardive dyskinesia, Acta Psychiatry Scand. 77, 369.
21. German, D.C., B.A. McMillen, M.K. Sanghera, S.I. Saffer and P.A. Shore, 1981, Effect of severe dopamine depletion on dopamine neuronal impulse flow and on tyrosine hydroxylase regulation, Brain Res. Bull. 6, 131.
22. Gunne, L.M. and J.-E. Häggström 1983, Reduction of nigral glutamic acid decarboxylase in rats with neuroleptic-induced oral dyskinesia, Psychopharmacology 81, 191.
23. Gunne L.M., J.-E. Häggström and B. Sjöquist, 1984, Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis, Nature 309, 347.
24. Hong, M., P. Jenner and C.D. Marsden, 1987, Comparison of the acute actions of amine-depleting drugs and dopamine receptor antagonists on dopamine function in the brain in rats, Neuropharmacology 26, 237.
25. Jenner, P. and C.D. Marsden, 1988, Adaptive changes in brain dopamine function as a result of neuroleptic treatment, in: Advances in Neurology, Vol. 49: Facial Dyskinesias, eds. J. Jankovic and E. Tolosa (Raven Press, New York) p. 417.
26. Jeste, D.V. and R.J. Wyatt, 1982, Therapeutic strategies against tardive dyskinesia, Arch. Gen. Psychiatry 39, 803.
27. Joyce, J.N., 1991, Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine, Exp. Neurol. 113, 277.
28. Kazamatsuri, H., C.P. Chien and J.O. Cole, 1972, Treatment of tardive dyskinesia. II. Short term efficacy of dopamine-blocking agents haloperidol and thiopropazate, Arch. Gen. Psychiatry 27, 100.
29. Keefe, K.A., J.D. Salamone, M.J. Zigmond and E.M. Stricker, 1989, Paradoxical kinesia in Parkinsonism is not caused by dopamine release - studies in an animal model, Arch. Neurol. 46, 1070.
30. Klawans, H.L., 1973, The pharmacology of tardive dyskinesias, Am. J. Psychiatry 130, 83.
31. Klawans, H.L., C.M. Tanner and A. Barr, 1984, The reversibility of "permanent" tardive dyskinesia, Clin. Neuropharmacol. 7, 153.
32. Kuczenski, R. and D.S. Segal, 1992, Regional norepinephrine response to amphetamine using dialysis: comparison to caudate dopamine, Synapse 11, 164.
33. 2 synergism are unrelated to changes in striatal receptor density, Synapse 12, 14.
34. Langer, S.Z. and S. Arbilla, 1984, The amphetamine paradox in dopaminergic neurotransmission, Trends Pharmacol. Sci. 5, 387.
35. Lublin, H. and J. Gerlach, 1988, Behavioural effects of dopamine D-1 and D-2 receptor agonists in monkeys previously treated with haloperidol, Eur. J. Pharmacol. 153, 239.
36. Lublin, H., J. Gerlach and L. Peacock, 1992, Effect of D1 and D2 agonists in primates withdrawn from long-term treatment with haloperidol: the potential role of dopamine D1 receptors in dyskinesia, Clin. Neuropharmacol. 15, 448.
37. Moore, K., 1978, Amphetamines: biochemical and behavioral actions in animals actions in animals, in: Handbook of Psychopharmacology (New York, Plenum Press) p. 41.
38. Neisewander, J.L., E. Castañeda and D.A. Davis, 1994, Dose-dependent differences in the development of reserpine-induced oral dyskinesia in rats: support for a model of tardive dyskinesia, Psychopharmacology 116, 79.
39. Neisewander, J.L., I. Lucki and P. McGonigle, 1991a, Behavioral and neurochemical effects of chronic administration of reserpine and SKF-38393 in rats, J. Pharmacol. Exp. Ther. 257, 850.
40. Neisewander, J.L., I. Lucki and P. McGonigle, 1991b, Neurochemical changes associated with the persistence of spontaneous oral dyskinesia in rats following chronic reserpine treatment, Brain Res. 558, 27.
41. Niddam, R., S. Arbilla, B. Scatton, T. Dennis and S.Z. Langer, 1985, Amphetamine induced release of endogenous dopamine in vitro is not reduced following pretreatment with reserpine, Naunyn-Schmied. Arch. Pharmacol. 329, 123.
42. Parker, E.M. and L.X. Cubeddu, 1986, Effects of d-amphetamine and dopamine synthesis inhibitors on dopamine and acetylcholine neurotransmission in the striatum. I. Release in the absence of vesicular transmitter stores, J. Pharmacol. Exp. Ther. 237, 179.
43. 2 receptor agonists and antagonists in monkeys withdrawn from long-term neuroleptic treatment, Eur. J. Pharmacol. 186, 49.
44. Quinton, R.M. and G. Halliwell, 1963, Effects of α-methyl DOPA and DOPA on the amphetamine excitatory response in reserpinized rats, Nature 200, 178.
45. Raiteri, M., F. Cerrito, A.M. Cervoni and G. Levi, 1979, Dopamine can be released by two mechanisms differentially affected by the dopamine transport inhibitor nomifensine, J. Pharmacol. Exp. Ther. 208, 195.
46. Robinson, T.E., J.B. Becker, A.E. Young, H. Akil and E. Castañeda, 1987, The effects of footshock stress on regional brain dopamine metabolism and pituitary beta-endorphin release in rats previously sensitized to amphetamine, Neuropharmacology 26, 679.
47. Ross, S.B., D.M. Jackson, E.M. Wallis and S.R. Edwards, 1988, Enhancement by a single dose of reserpine (plus alpha methyl-p-tyrosine) of the central stimulatory effects evoked by dopamine D-1 and D-2 agonists in the mouse, Naunyn-Schmied. Arch. Pharmacol. 337, 512.
48. Scheel-Krüger, J., 1971, Comparative studies of various amphetamine analogues demonstrating different interactions with the metabolism of the catecholamines in the brain, Eur. J. Pharmacol. 14, 47.
49. Scheel-Krüger, J. and J. Arnt, 1985, New aspects on the role of dopamine, acetylcholine, and GABA in the development of tardive dyskinesia, Psychopharmacology Suppl. 2, 46.
50. See, R.E., 1991, Striatal dopamine metabolism increases during long-term haloperidol administration in rats but shows tolerance in response to acute challenge with raclopride, Neurosci. Lett. 129, 265.
51. See, R.E., 1993, Assessment of striatal extracellular dopamine and dopamine metabolites by microdialysis in haloperidol-treated rats exhibiting oral dyskinesia, Neuropsychopharmacology 9, 101.
52. See, R.E., M.A. Chapman, C.E. Murray and M. Aravagiri, 1992, Regional differences in chronic neuroleptic effects on extracellular dopamine activity, Brain Res. Bull. 29, 473.
53. Shannak, K.S. and O. Hornykiewicz, 1980, Brain monoamines in rhesus monkey during long-term neuroleptic administration, Adv. Biochem. Psychopharmacol. 24, 315.
54. Shonecker, M., 1957, Ein eigentümliches Syndrom in eralen Bereich bei Megaphen Applikation, Nervenartz 28, 34.
55. Smith, C.B., 1963, Enhancement by reserpine and α-methyldopa of the effects of d-amphetamine upon the locomotor activity of mice, J. Pharmacol. Exp. Ther. 142, 343.
56. Smith, J.M. and R.J. Baldessarini, 1980, Changes in prevalence, severity, and recovery in tardive dyskinesia with age, Arch. Gen. Psychiatry 37, 1368.
57. 1 receptors in the reserpine-treated mouse, Neuroscience 22, 179.
58. Stoessl, A.J., C.T. Dourish and S.D. Iversen, 1989, Chronic neuroleptic-induced mouth movements in the rat: suppression by CCK and selective dopamine D1 and D2 receptor antagonists, Psychopharmacology 98, 372.
59. Stolk, J.M. and R.H. Rech, 1967, Enhanced stimulant effects of d-amphetamine on the spontaneous locomotor activity of rats treated with reserpine, J. Pharmacol. Exp. Ther. 158, 140.
60. Sulzer, D., N.T. Maidment and S. Rayport, 1993, Amphetamine and other weak bases act to promote reverse transport of dopamine in ventral midbrain neurons, J. Neurochem. 60, 527.
61. Tarsy, D. and R.J. Baldessarini, 1974, Behavioral supersensitivity to apomorphine following chronic treatment with drugs which interfere with the synaptic function of catecholamines, Neuropharmacology 13, 927.
62. Tarsy, D., 1983, History and definition of tardive dyskinesia, Clin. Neuropharmacol. 6, 91.
63. Uhrbrand, L. and A. Faurbye, 1960, Reversible and irreversible dyskinesia after treatment with perphenazine, chlorpromazine, reserpine, and electroconvulsive therapy, Psychopharmacologia 1, 408.
64. Van Rossum, J.M., J.B. Van der Schoot and J.A. Hurkmans, 1962, Mechanism of action of cocaine and amphetamine in the brain, Experientia 18, 229.